Overexpression of TNFSF11 reduces GPX4 levels and increases sensitivity to ferroptosis inducers in lung adenocarcinoma

• Published in: Journal of translational medicine Vol. 22; no. 1; pp. 340 - 18
• Main Authors: Li, Zizhen, Lu, Wenhua, Yin, Feng, Zeng, Peiting, Li, Heping, Huang, Amin
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09.04.2024; BioMed Central; BMC
• Subjects: Accuracy; Adenocarcinoma; Adenocarcinoma of Lung - genetics; Analysis; Antibodies; Biological Assay; Biomarkers; Cancer; Cancer therapies; Care and treatment; Databases, Factual; Development and progression; Diagnosis; DNA microarrays; Dosage and administration; Erastin; Ferroptosis; Ferroptosis - genetics; Gene expression; Genes; Genetic aspects; GPX4; Health aspects; Humans; Immunotherapy; LUAD; Lung cancer; Lung Neoplasms - genetics; Malignancy; Medical prognosis; Metastasis; Patient outcomes; Precision medicine; Prostate; RANK Ligand; Respiratory agents; RSL3; Therapeutic targets; TNFSF11; Tumor cells; Tumors; China; Taiwan; Erastin; Ferroptosis; TNFSF11; GPX4; RSL3; LUAD
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-024-05112-y

Lung adenocarcinoma (LUAD), the most common and lethal subtype of lung cancer, continues to be a major health concern worldwide. Despite advances in targeted and immune therapies, only a minority of patients derive substantial benefits. As a result, the urgent need for novel therapeutic strategies t...